Sola Security Launches Lumina, an Autonomous Security Deep Research Platform for Actionable Risk Intelligence Capitola Secures $15.6M in Series A Funding Round Led by Munich Re Ventures along with Lightspeed Venture Partners
New Capital Will Be Invested in Further Development of Technology for Retail and Commercial Insurance…
Genesis Energy, L.P. Announces Executive Leadership Promotions
HOUSTON–(BUSINESS WIRE)–Genesis Energy, L.P. (NYSE: GEL) announced today several executive leadership promotions, effective immediately. Ryan…
Allegion Appoints Ellen Rubin to Board of Directors
DUBLIN–(BUSINESS WIRE)–Allegion plc (NYSE: ALLE), a leading global security products and solutions provider, has appointed…
Fiber Access Extension technology set for critical role as the race for MultiGigabit speeds intensifies
With an increasing number of US telecom and fiber operators offering MultiGigabit services (2 Gigabit…
Change to Financial Calendar for 2023 and update regarding class action lawsuit in United States
Company announcement Orphazyme A/SNo. 01/2023 Ole Maaløes Vej 3DK-2200 Copenhagen Nwww.orphazyme.com Company Registration No. 32266355…
Glycotope Presents Glyco-Engineered Cell Lines at the 2023 American Association for Cancer Research (AACR) Meeting
Glycotope Presents Glyco-Engineered Cell Lines at the 2023 American Association for Cancer Research (AACR) Meeting…
Mendus AB: Mendus (publ) publishes the Annual Report for 2022 and holds investor call on April 17th
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today…
Cellectis Presents Preclinical Data on TALEN®-edited MUC1 CAR T-cells to Enhance Efficacy in Targeting Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting
NEW YORK, April 17, 2023 (GLOBE NEWSWIRE) — Cellectis (the “Company”) (Euronext Growth: ALCLS –…
argenx and Genmab Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
Genmab and argenx have entered into a multiyear collaboration bringing together capabilities to jointly discover, develop and commercialize…
Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
Media Release COPENHAGEN, Denmark; April 17, 2023 Genmab and argenx have entered a multiyear collaboration bringing together capabilities…
Smart Immune receives $5 million investment to further its thymus-empowered ProTcell therapy platform
Smart Immune receives $5 million investment to further its thymus-empowered ProTcell therapy platform The new…
PlayMining Web3 Gaming Platform Announces Game Launch and NFT Presale for “Lost Archive +”
PlayMining Game ‘Lost Archive +’ Launches in May, NFT Presale in late April ‘Lost Archive…
Synergy House Berhad Obtains Approval for ACE Market Listing, Engages Kenanga IB as Underwriter
KUALA LUMPUR, Apr 17, 2023 – (ACN Newswire) – SYNERGY HOUSE BERHAD, a cross-border e-commerce…
Content Remains King in the Future of Video in India
MUMBAI, INDIA, Apr 17, 2023 – (ACN Newswire) – The Asia Video Industry Association’s (AVIA)…
OPEX Partners with Advanced Robotics in Hungary to Provide Innovative Warehouse Automation Solutions
Advanced Robotics Becomes the First OPEX Integrator to Implement OPEX Perfect Pick Goods-to-Person System in…
Singapore Continues To Lead the Way in Asia in Judicial Blocking of Illegal Streaming Sites, but More Can Be Done
Singapore, Apr 17, 2023 – (ACN Newswire) – The Asia Video Industry Association’s Coalition Against…
Inflight Entertainment Features Indonesia as a Partner Country for Hannover Messe 2023
JAKARTA, Apr 17, 2023 – (ACN Newswire) – Within a few days, Hannover Messe 2023,…
SNBL to Acquire Satsuma Pharmaceuticals
Transaction delivers immediate value and liquidity to Satsuma stockholders SNBL to acquire all outstanding shares…
Over half of consumers have been a victim of financial crime according to latest report from Feedzai
Feedzai’s new report reveals a lack of awareness of scams is putting many consumers at…
Vaxcyte to Host Webcast and Conference Call to Discuss Results from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate in Adults Aged 65 and Older and Full Six-Month Safety Data from Both Adult Phase 2 Studies
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage…